title: [A comparison of efficacy and safety of linezolid versus vancomycin for the treatment of infections in patients after allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To compare the efficacy and safety of linezolid and vancomycin in patients diagnosed as gram positive bacterial infections after receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  A total of 131 patients who were confirmed or suspected as gram positive coccal infections after allo-HSCT were enrolled in our study from July 2010 to December 2012. Patients were administrated with linezolid (600 mg every 12 h) or vancomycin (1 g every 12 h). Clinical efficacy and safety were compared between the two groups.
  
  
  RESULTS
  A total of 136 cases were detected gram positive coccal infections, among whom 120 cases were evaluable. Finally, 37 cases receiving linezolid and 83 cases receiving vancomycin were enrolled in this study. Clinical cure rates of infections were 81.1% (30/37) and 88.0% (73/83) in linezolid and vancomycin groups, respectively(P=0.319). The incidence of adverse reactions was similar in the two groups[50.0% (23/40) vs 45.6% (41/90), P=0.623]. Drug-related renal function injury was mild [6.5% (3/46) vs 6.7% (6/90), P=1.000]. The occurrence of liver damage with moderate and severe elevation enzymes was also similar between the two groups [2.2% (1/46) vs 6.7% (6/90), P=0.244]. As for hematologic events, linezolid was not found to have a negative effect on hematopoietic reconstitution.
  
  
  CONCLUSIONS
  Linezolid is as effective as vancomycin in the treatment of gram positive bacterial infections after allo-HSCT. Safety of Linezolid is also comparable with that of vancomycin, which needs to be further studied due to the complex interaction of medication in this special population.
authors.forename: Jie
authors.initials: J
authors.lastname: Tian
authors.forename: Zhengli
authors.initials: Z
authors.lastname: Xu
authors.forename: Daihong
authors.initials: D
authors.lastname: Liu
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Huang
authors.forename: Kaiyan
authors.initials: K
authors.lastname: Liu
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Yuhong
authors.initials: Y
authors.lastname: Chen
authors.forename: Yao
authors.initials: Y
authors.lastname: Chen
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Fengrong
authors.initials: F
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Chenhua
authors.initials: C
authors.lastname: Yan
authors.affiliation: Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
authors.forename: Lanping
authors.initials: L
authors.lastname: Xu
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000069349:Linezolid / Q000627:therapeutic use*; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D000069349:Linezolid